MA54450A - Biomarqueurs de maladie lysosomale et leurs méthodes d'utilisation - Google Patents

Biomarqueurs de maladie lysosomale et leurs méthodes d'utilisation

Info

Publication number
MA54450A
MA54450A MA054450A MA54450A MA54450A MA 54450 A MA54450 A MA 54450A MA 054450 A MA054450 A MA 054450A MA 54450 A MA54450 A MA 54450A MA 54450 A MA54450 A MA 54450A
Authority
MA
Morocco
Prior art keywords
methods
disease biomarkers
lysosomal disease
lysosomal
biomarkers
Prior art date
Application number
MA054450A
Other languages
English (en)
Inventor
Annie Arguello
Giuseppe Astarita
Akhil Bhalla
Jessica R Blumenfeld
Paolo Gilbert Di
Anastasia Henry
Alicia A Nugent
Julie Ullman
Junhua Wang
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of MA54450A publication Critical patent/MA54450A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
MA054450A 2018-12-10 2019-12-10 Biomarqueurs de maladie lysosomale et leurs méthodes d'utilisation MA54450A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862777599P 2018-12-10 2018-12-10
US201962860039P 2019-06-11 2019-06-11
US201962869387P 2019-07-01 2019-07-01
US201962912253P 2019-10-08 2019-10-08

Publications (1)

Publication Number Publication Date
MA54450A true MA54450A (fr) 2021-10-20

Family

ID=69024750

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054450A MA54450A (fr) 2018-12-10 2019-12-10 Biomarqueurs de maladie lysosomale et leurs méthodes d'utilisation

Country Status (7)

Country Link
US (1) US20220025065A1 (fr)
EP (1) EP3894864A2 (fr)
JP (2) JP2022513735A (fr)
CN (2) CN113826015A (fr)
CA (1) CA3121927A1 (fr)
MA (1) MA54450A (fr)
WO (1) WO2020123511A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS63818B1 (sr) 2017-02-17 2023-01-31 Denali Therapeutics Inc Konstruisani polipeptidi za vezivanje za receptor transferina
JP7543290B2 (ja) 2019-02-20 2024-09-02 デナリ セラピューティクス インコーポレイテッド 抗ｔｒｅｍ２抗体及びその使用方法
AU2020252554B2 (en) 2019-04-03 2026-05-28 Denali Therapeutics Inc. Formulations of protein molecules comprising iduronate 2-sulfatase
BR112022012230A2 (pt) 2019-12-23 2022-08-30 Denali Therapeutics Inc Variantes de progranulina
US11124567B2 (en) 2020-01-13 2021-09-21 Denali Therapeutics Inc. Anti-TREM2 antibodies and methods of use thereof
US20250018015A1 (en) 2021-07-23 2025-01-16 Denali Therapeutics Inc. Methods for the treatment of hunter syndrome
IL311003A (en) 2021-08-25 2024-04-01 Denali Therapeutics Inc Anti-2HER antibodies and methods of using them
CN115032377B (zh) * 2022-08-11 2022-11-01 裕菁科技(上海)有限公司 一种粘多糖贮积症生物标记物及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0128498D0 (en) * 2001-11-28 2002-01-23 Inst Of Child Health International standards for sphingolipids
JP4667749B2 (ja) * 2002-01-17 2011-04-13 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド スフィンゴ脂質代謝および／またはシグナル伝達の調節のための組成物および方法
AU2008245578A1 (en) * 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
WO2010011605A2 (fr) * 2008-07-21 2010-01-28 Otonomy, Inc. Compositions à libération contrôlée modulant la structure otique et modulant le système immunitaire naturel et procédés de traitement de troubles otiques
GB201114909D0 (en) * 2011-08-30 2011-10-12 San Raffaele Centro Fond Biomarkers for lysosomal storage disorders
JP2013116221A (ja) * 2011-12-02 2013-06-13 Toyota Motor Corp 移乗ロボット
JP2016525676A (ja) * 2013-05-02 2016-08-25 ザ チャンセラー，マスターズ アンド スカラーズ オブ ザ ユニバーシティ オブ オックスフォード リピドミックバイオマーカー
US20180348239A1 (en) * 2014-11-19 2018-12-06 Centogene Ag Method for the Diagnosis of Niemann-Pick Disease Using a Biomarker
MA43968A (fr) * 2016-02-03 2018-12-12 Univ Pennsylvania Thérapie génique pour traiter la mucopolysaccharidose de type i
JP7225115B2 (ja) * 2017-01-17 2023-02-20 ザ チルドレンズ メディカル センター コーポレーション リソソーム蓄積症およびリソソーム蓄積障害を処置するための組成物および方法
EP4628586A3 (fr) 2017-02-17 2026-01-14 Denali Therapeutics Inc. Modeles transgeniques du recepteur de la transferrine
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
WO2022029281A1 (fr) * 2020-08-06 2022-02-10 Aarhus Universitet Peptides cycliques et leurs utilisations

Also Published As

Publication number Publication date
CN120044247A (zh) 2025-05-27
JP2022513735A (ja) 2022-02-09
EP3894864A2 (fr) 2021-10-20
WO2020123511A2 (fr) 2020-06-18
US20220025065A1 (en) 2022-01-27
WO2020123511A3 (fr) 2020-07-23
JP2024156744A (ja) 2024-11-06
CA3121927A1 (fr) 2020-06-18
CN113826015A (zh) 2021-12-21

Similar Documents

Publication Publication Date Title
EP3852805A4 (fr) Anticorps anti-lilrb2 et leurs méthodes d'utilisation
EP3856786A4 (fr) Constructions d'imagerie de cd8 et leurs méthodes d'utilisation
EP3959318A4 (fr) Compositions d'oligonucléotides et leurs méthodes d'utilisation
MA50957A (fr) Anticorps anti-tigit et leurs méthodes d'utilisation
EP3917564A4 (fr) Anticorps anti-claudine 18 et leurs méthodes d'utilisation
EP3700527A4 (fr) Inhibiteurs de papd5 et leurs méthodes d'utilisation
MA49288A (fr) Reactifs particulaires oligomères et leurs méthodes d'utilisation
MA45123A (fr) Anticorps anti-tim-3 et leurs méthodes d'utilisation
EP3383430A4 (fr) Anticorps et leurs méthodes d'utilisation
MA44526A (fr) Oxystérols et leurs méthodes d'utilisation
EP3319611A4 (fr) Oxystérols et leurs méthodes d'utilisation
MA50354A (fr) Anticorps ciblant le cd137 et leurs méthodes d'utilisation
EP3368016A4 (fr) Polysaccharides réduits et oxydés et leurs méthodes d'utilisation
EP3337517A4 (fr) Conjugués anticorps-médicaments anti-dll3 et méthodes d'utilisation
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
EP3525583A4 (fr) Anticorps anti-c1s et leurs méthodes d'utilisation
EP3684819A4 (fr) Anticorps anti-ykl40 et méthodes d'utilisation
EP3383917A4 (fr) Nouveaux anticorps anti-claudine et méthodes d'utilisation
EP3728323A4 (fr) Anticorps anti-fzd et méthodes d'utilisation
MA43282A (fr) Nouveaux anticorps anti-emr2 et méthodes d'utilisation associées
EP3706777A4 (fr) Variants de type iia du récepteur de l'activine et leurs méthodes d'utilisation
MA50958A (fr) Anticorps anti-apoc3 et leurs méthodes d'utilisation
MA53492A (fr) Anticorps anti-cd33 et leurs méthodes d'utilisation
EP3743109A4 (fr) Anticorps anti-mica/b et leurs méthodes d'utilisation
MA46422A (fr) Oligonucléotides modifiés et méthodes d'utilisation